Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.
about
Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancerHormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancerAndrogen deprivation therapy as backbone therapy in the management of prostate cancerPredictive clinical indicators of biochemical progression in advanced prostate cancer patients receiving Leuplin depot as androgen deprivation therapyDesign and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.New developments in the medical management of prostate cancer.Management of Hormone-Sensitive and Hormone-Refractory Metastatic Prostate Cancer.Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group.Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support.Drug-induced gynecomastia.Safety of antiandrogen therapy for treating prostate cancer.Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer.The treatment of prostate cancer: an overview of current options.Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer.Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic reviewCurrent status of endocrine therapy in localized prostate cancer: cure has become a strong possibility.Gynecomastia in patients with prostate cancer: update on treatment options.Rising prostate-specific antigen after primary prostate cancer therapy.Can prophylactic breast irradiation contribute to cardiac toxicity in patients with prostate cancer receiving androgen suppressing drugs?Germline predictors of androgen deprivation therapy response in advanced prostate cancerThe changing pattern of management for hormone-refractory, metastatic prostate cancer.Maximum androgen blockade: a clinical update.Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.Goserelin acetate in combination with radiotherapy for prostate cancer.Leuprorelin depot injection: patient considerations in the management of prostatic cancerMultiple intracrine hormonal targets in the prostate: opportunities and challenges.Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.New horizons in prostate cancer imaging.Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer.PSA screening for prostate cancer: why so much controversy?Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: A 12 month-prospective observational study.Blockade of testicular and adrenal androgens in prostate cancer treatment.Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer.Emerging technology: applications of Raman spectroscopy for prostate cancer.Concept and viability of androgen annihilation for advanced prostate cancer.Role of maximum androgen blockade in advanced prostate cancer.Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancerWhy phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.Which patients with prostate cancer are actually candidates for hormone therapy?
P2860
Q26739738-E4C18F51-F8EE-4763-B71A-534830011CB1Q26773634-428B52FF-503A-4B6D-A2F7-1A6498B54826Q28071795-246D9501-0666-4F29-808F-CD9570F3514BQ28541955-EA52092A-2B78-4F44-80F1-5262A032C8F1Q33566395-332B45D1-443E-47BC-A13B-56BB848A5413Q33566738-2C5C4CDA-6748-4496-A30A-91EE70E2B00AQ33889276-C0CA7A0D-3A0A-4F58-941C-0EC28450D605Q33890397-2180C898-5FFF-411C-B759-6CB4D6CDFED9Q33910607-572BC2B0-3E7D-43A3-B4E0-6F98980B7351Q34312712-01858973-0D56-4C4E-979C-A5D8F860D3E4Q34441134-3EC4D2BB-C07C-4F86-9049-168A3312368AQ34441487-CA91C1D5-6B98-4006-8D3A-EE70473781DFQ34552438-68716313-F903-48CA-95BD-72D32418021FQ35738188-1DB5570D-E93C-4324-84F6-0FDFA95294CFQ35840364-33BBE1F5-90CE-496B-A06E-65D38E1EC771Q36039229-25D91749-B0BB-4254-8B51-F31139044205Q36375981-68F80B67-621C-427D-AF5B-5FA37B908124Q36395149-436B9708-4779-4CE1-9CEE-E9D6ED73BFBCQ36473630-8D914182-F4C9-4D27-AF2A-4E2BB1795E76Q36512896-1FBF4272-A74D-4089-B421-6CE10C5A741CQ36519880-30655355-7914-4BF2-8406-3738F863DAD4Q36598408-BCBBFB86-B384-4817-B6BF-8CB3BE4B4B01Q36677464-265F039C-268B-4E15-A737-B4B78AB7B6D5Q36719711-08B995CA-0300-4FDF-A170-423489B24AE5Q36823588-75099931-98FC-4F7C-9C34-5C9F7FC3ECA6Q36861779-93FAA0E4-8FD3-4A69-A87F-02BA2507C508Q37084596-A611895F-C9AE-4E4D-BEEE-47098B20434DQ37134564-242A1319-3ADE-4397-9EF6-4F520B47A587Q37242030-D1986AE2-9640-4F0D-96CB-BF80F7F29283Q37392579-793C7BAB-A52E-4BCB-8F95-21A116D6C5B9Q37436987-3B0DB9A4-CBFB-4541-BC8A-DA2971FBBB0CQ37681882-9CB34475-2DEC-40A5-8B67-68812C995BFFQ37829637-A98DB634-6C47-4699-9EF4-61E4A80A6339Q38130174-C4EE5AC4-E824-4056-A600-140C8D96666CQ38186589-17AB5682-EBAC-430B-AC83-96BCAEF83111Q38207556-9477C752-7AEB-4C89-9BBB-3F14DE32DF16Q39977084-B611474F-B254-4F91-B74E-1AD35DE61DA0Q42322498-CC741E4A-86D1-4B07-8FDE-DA4006F54DD5Q43629563-8B984380-3BCA-4573-A5AD-0A0CAC84453FQ45233216-B1DFBEC3-6D75-4F50-B592-5705D06B5B25
P2860
Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Maximal androgen blockade: fin ...... oup and the EORTC Data Center.
@ast
Maximal androgen blockade: fin ...... oup and the EORTC Data Center.
@en
type
label
Maximal androgen blockade: fin ...... oup and the EORTC Data Center.
@ast
Maximal androgen blockade: fin ...... oup and the EORTC Data Center.
@en
prefLabel
Maximal androgen blockade: fin ...... oup and the EORTC Data Center.
@ast
Maximal androgen blockade: fin ...... oup and the EORTC Data Center.
@en
P2093
P356
P1433
P1476
Maximal androgen blockade: fin ...... oup and the EORTC Data Center.
@en
P2093
Keuppens F
Sylvester R
de Moura JL
P304
P356
10.1159/000019546
P407
P577
1998-01-01T00:00:00Z